Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : CB307
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Crescendo Biologics Ltd
Deal Size : Undisclosed
Deal Type : Agreement
Angle PLC, Crescendo Biologics Ink Clinical Services Contract
Details : Under the agreement, Crescendo will use ANGLE's recently launched Portrait Flex assay in its Phase 1 trial investigating the safety and efficacy of CB307, a first-in-class PSMA x CD137 half-life extended bispecific, for treating patients with PSMA positi...
Brand Name : CB307
Molecule Type : Large molecule
Upfront Cash : Undisclosed
April 13, 2023
Lead Product(s) : CB307
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Crescendo Biologics Ltd
Deal Size : Undisclosed
Deal Type : Agreement
LOOKING FOR A SUPPLIER?